Plastic may be greener than stainless steel, but industry still needs to find a more recyclable alternative for biomanufacturing systems according to Greenpeace.
Fujifilm Diosynth Biotechnologies has opened a mammalian cell culture-based manufacturing facility in the UK in the latest stage of an effort to expand its business.
GE Healthcare Life Sciences has agreed to build a modular biopharmaceutical factory in China for JHL Biotech, which could be a model for ways to grow local manufacturing in emerging markets.
The US Department of Health and Human Services (HHS) says it is buying cell lines to manufacture anthrax antitoxins on top of its $196m (€145m) deal with GlaxoSmithKline to stockpile Raxibacumab.
Horizon Discovery has licensed a zinc finger nuclease (ZFN) technology from Sigma-Aldrich and says the combination with its own platform will be “a big step forward in gene editing.”
Mitsubishi Tanabe Pharma (MTPC) is closer to adding two plant-based expression techs to its manufacturing arsenal after Medicago shareholders back its takeover bid.
Pall Corporation says it will continue to invest in single-use systems after reporting substantially higher growth in sales compared to stainless steel systems for the 2013 FY.
Biotech company Haplogen and the Center for Molecular Medicine of the Austrian Academy of Sciences this week released the largest collection of human cell lines that are deficient for single genes.
Large arrays of identical nanosensors could improve MAb production, identify glycosylation and pinpoint the best cell lines for biomanufacturing say US researchers.
Agilent Technologies is partnering with SomaLogic to expand the dissemination of Soma’s proteomic assay to at least five academic and contract research centers by the end of the year as demand for the tool has skyrocketed among biopharma companies.
New flexible vaccine technology could pave the way for pneumococcal, TB and staphylococcus aureus vaccines that are cheaper to produce and more effective.
Adapting stainless steel facilities to incorporate increased use of disposable technology can help reduce costs and improve quality compliance, say TFS and Lonza.
Genesis Biopharma has merged with Lion Biotechnologies and says its tumor-infiltrating lymphocyte (TIL) technology can offer higher potency cancer drugs with lower manufacturing costs.
Industry has been slow to implement single-use technologies for microbial cultivations, according to Sartorius which has launched a new bioreactor gas sensor.
As biopharma manufacturers look to save money setting up facilities and cleaning equipment, companies are increasingly turning to single-use technology and especially single-use bioreactors.
After patent expiration led to facility shuttering and cutbacks, Irish manufacturing will receive a $130m (€100m) boost to prepare for Pfizer’s new pipeline, the company says.
The Brazilian Government is to fund a new facility to produce the Protalix-Pfizer Gaucher's disease drug Uplyso as part of a supply and tech transfer deal worth $280m (€212m).
Lonza has launched a service to help biopharmas decide if promising protein drug candidates are worth developing, from an immunogenicity and manufacturing standpoint.
Early clinical research organisation Celerion has added a containment room to its UK facility in response to client demand for live biologics and vaccine studies.
Over the last decade single-use technologies have moved into manufacturing scales and are increasingly being deployed worldwide, according to Thermo Fisher Scientific.
ASI has teamed up with Chromatan in order to deliver single-use and column-free capture purification services which could save clients 65% in chromatography costs in clinical manufacturing.
Thermo Fisher Scientific has agreed to purchase genetic testing equipment maker Life Technologies for $13.6B in one of the biggest acquisitions of the year.
GE Healthcare and iBio are in talks about future projects after confirming they are working on a plant-based vaccine manufacturing site for Brazilian drugmaker Fiocruz/Bio-Manguinhosin.
As anticipation swells over how the biosimilar market will shape up in the US, some contract biologic manufacturing executives don’t seem to think the size of the market is worth all of the hype yet.
Outsourcing-Pharma.com brings you a round-up of the latest contract manufacturing facility additions, including news from Boehringer Ingelheim, Cambridge Major Laboratories, and B. Braun Group.
Cobra Biologics claims a new micro bioreactor technology it has adopted can cut three months off cell line development timelines and facilitate faster production scale-up.
Catalent has replaced all stainless steel bioreactors at its biologics facility in Middleton, Wisconsin with single-use techs citing cost and flexibility advantages.
The implementation of single use technology in the biopharmaceutical fill and finish process has seen a massive uptick recently because of better industry understanding, according to Pall’s Bruce Rawlings.
Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.
